Bicyclic pyrrolidine inhibitors of Toxoplasma gondii phenylalanine t-RNA synthetase with antiparasitic potency in vitro and brain exposure
Chloe C. Ence, Taher Uddin, Julien BorreliD, Payal MittaliD, Han XieiD, Jochen ZolleriD, Amit SharmaiD, Eamon ComeriD, Stuart L. SchreiberiD, Bruno N. MelilloiD, L. David SibleyiD, Arnab K. ChatterjeeiD
Abstract
Previous studies have shown that bicyclic azetidines are potent and selective inhibitors of apicomplexan phenylalanine tRNA synthetase (PheRS), leading to parasite growth inhibition in vitro and in vivo, including in models of Toxoplasma infection. Despite these useful properties, additional optimization is required for the development of efficacious treatments of toxoplasmosis from this inhibitor series, in particular to achieve sufficient exposure in the brain. Here, we describe a series of PheRS inhibitors built on a new bicyclic pyrrolidine core scaffold designed to retain the exit-vector geometry of the isomeric bicyclic azetidine core scaffold while offering avenues to sample diverse chemical space. Relative to the parent series, bicyclic pyrrolidines retain reasonable potency and target selectivity for parasite PheRS vs. host. Further structure-activity relationship studies revealed that the introduction of aliphatic groups improved potency, ADME and PK properties, including brain exposure. The identification of this new scaffold provides potential opportunities to extend the analog series to further improve selectivity and potency and ultimately deliver a novel, efficacious treatment of toxoplasmosis. Lay abstractThe inhibition of protein synthesis in parasites has emerged as an attractive strategy to target parasitic diseases such as malaria, cryptosporidiosis, and toxoplasmosis. In this study, we report a new series of small molecules that inhibit the enzyme responsible for loading the amino acid phenylalanine onto its cognate tRNA in the parasite species Toxoplasma, directly upstream of protein synthesis. We show that small molecules in this new series inhibit Toxoplasma parasite growth at low concentrations, and that, orally administered to mice, these molecules achieve high concentrations in the brain, which hold promise for the treatment of forms of toxoplasmosis that result from parasitic brain infection.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 1.10
- Field percentile
- top 32%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Minimum inoculum of resistance assay for evaluating for anti-toxoplasmosis compounds that target phenyl alanine tRNA synthetase
Taher Uddin, Payal Mittal, … L. David Sibley·bioRxiv·Mar 3, 2026
- Orally Bioavailable Endochin-like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts
J. S. Doggett, T. L. Schultz, … V. B. Carruthers·bioRxiv·Mar 19, 2020
- A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo
Stanley C. Xie, Chia-Wei Tai, … Leann M. Tilley·PLoS PathogensPeer-reviewed·Dec 9, 2024
- Identification and characterization of thiamine analogues with antiplasmodial activity
Imam Fathoni, Terence C. S. Ho, … Kevin J. Saliba·Antimicrobial Agents and ChemotherapyPeer-reviewed·Oct 29, 2024
- Screening of purine nucleoside analogues against intracellular Toxoplasma gondii.
Hamza A. A. Elati, Serge Van Calenbergh, … Harry P. de Koning·International Journal for Parasitology Drugs and Drug ResistancePeer-reviewed·Apr 10, 2026
- Legacy 4(1H)-quinolone scaffolds activity against acute and chronic Toxoplasma gondii infection
Melissa A. Sleda, Khaly Diagne, … Silvia N.J. Moreno·ACS Infectious DiseasesPeer-reviewed·May 26, 2026